Scarica l'app Stockscreener
0.868
2.63%
-0.0234
Dopo l'orario di chiusura:
.87
0.002
+0.23%
Cognition Therapeutics Inc Borsa (CGTX) Ultime notizie
CGTX Technical Analysis & Stock Price Forecast - Intellectia AI
CGTX Should I Buy - Intellectia AI
Cognition Therapeutics plans late-stage trial for dementia drug By Investing.com - Investing.com Australia
Cognition Therapeutics plans late-stage trial for dementia drug - Investing.com
Cognition Therapeutics CEO Issues Letter to Shareholders - globenewswire.com
Q1 Earnings Forecast for CGTX Issued By HC Wainwright - MarketBeat
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation - Sahm
Cognition Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Receives Buy Rating from Chardan Capital - MarketBeat
Cognition Therapeutics posts narrower 2025 loss, eyes DLB trial By Investing.com - Investing.com South Africa
Cognition Therapeutics Reports 2025 Financial Results and Advances Zervimesine for DLB Psychosis and Alzheimer’s Clinical Trials - minichart.com.sg
Cognition Therapeutics Inc (CGTX) Q4 2025 Earnings Call Highlights: Promising Developments in ... By GuruFocus - Investing.com Canada
Cognition Therapeutics Advances Zervimesine (CT1812) for Alzheimer’s and Dementia—Clinical Results, Pipeline, and Strategic Overview - minichart.com.sg
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress - TipRanks
Cognition Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Earnings Call Summary | Cognition Therapeutics(CGTX.US) Q4 2025 Earnings Conference - 富途牛牛
Cognition Therapeutics Q4 Earnings Call Highlights - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Posts Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Earnings call transcript: Cognition Therapeutics Q4 2025 shows reduced losses - Investing.com
Cognition Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
CGTX: Zervimesine advances toward DLB psychosis registration, with strong data and solid cash position - TradingView
Earnings call transcript: Cognition Therapeutics Q4 2025 shows reduced losses By Investing.com - Investing.com South Africa
CGTX: Zervimesine advances for DLB psychosis with strong data, regulatory focus, and improved 2025 financials - TradingView
Cognition Therapeutics posts narrower 2025 loss, eyes DLB trial - Investing.com
COGNITION THERAPEUTICS ($CGTX) Releases Q4 2025 Earnings - Quiver Quantitative
Cognition Therapeutics 10-K: Net loss $23.5M, EPS $(0.32) - TradingView
Zervimesine pipeline and grant backing at Cognition (NASDAQ: CGTX) - Stock Titan
Cognition Therapeutics (NASDAQ: CGTX) narrows 2025 loss, funds into Q2 2027 - Stock Titan
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update - The Manila Times
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical ... - Caledonian Record
Cognition Therapeutics (CGTX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Cognition Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Zervimesine Demonstrates Symptom Slowing in Phase 2 SHIMMER Trial for Dementia With Lewy Bodies - Neurology Live
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results - The Globe and Mail
Cognition presents data on dementia drug zervimesine at conference By Investing.com - Investing.com South Africa
CGTX PE Ratio & Valuation, Is CGTX Overvalued - intellectia.ai
Cognition presents data on dementia drug zervimesine at conference - Investing.com
Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 - Bitget
Cognition Therapeutics Presents Promising Phase 2 Results of Zervimesine for Dementia with Lewy Bodies at AD/PD 2026 Conference - Quiver Quantitative
Cognition Therapeutics Presents Evidence of Zervimesine’s - GlobeNewswire
Cognition Therapeutics (CGTX) Stock Analysis Report | Financials & Insights - Benzinga Japan
Aug Intraday: Can Cognition Therapeutics Inc lead its sector in growthQuarterly Risk Review & Safe Entry Point Identification - baoquankhu1.vn
MACD Signal: What is the dividend yield of Cognition Therapeutics IncDividend Hike & AI Based Trade Execution Alerts - baoquankhu1.vn
Cognition Therapeutics shifts focus to DLB psychosis treatment By Investing.com - Investing.com Australia
Cognition Therapeutics shifts focus to DLB psychosis treatment - Investing.com Nigeria
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis - Bitget
Cognition Therapeutics Advances Zervimesine for DLB Psychosis - TipRanks
Cognition Therapeutics, Inc. Announces Advancement of Zervimesine Development for Dementia with Lewy Bodies Psychosis Treatment - Quiver Quantitative
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):